HCT contract signed with ILiAD Biotechnologies

Summary by AI BETAClose X

hVIVO plc has secured a contract to conduct the world's first pivotal Phase III human challenge trial for ILiAD Biotechnologies' whooping cough vaccine candidate, BPZE1. This trial, hVIVO's largest to date, will involve over 500 participants and is expected to generate significant revenue, with the majority recognised in 2026 and 2027, contributing strongly to near and mid-term financial performance. The study will assess BPZE1's efficacy against the current standard of care and is crucial for ILiAD's future marketing applications to global regulatory agencies.

Disclaimer*

Companies

Hvivo (HVO)
UK 100

Latest directors dealings